We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Pathology Workflow Uses AI for Analyzing Patient Samples

By LabMedica International staff writers
Posted on 15 Jun 2022
Print article
Image: Aiforia Clinical Suite Viewer has received CE-IVD marking (Photo courtesy of Aiforia Technologies)
Image: Aiforia Clinical Suite Viewer has received CE-IVD marking (Photo courtesy of Aiforia Technologies)

Rising healthcare costs, a reduction in the number of medical professionals specializing in pathology while cancer rates continue to increase inevitably drive a demand for more sophisticated and efficient technology. Given the current clinical pathology landscape, there is a need for tools to standardize diagnostics, reduce inter- and intra-observer variability and enable the extraction of large amounts of complex data in significantly reduced times. Now, a cloud-based platform enables a holistic approach to cancer diagnostics and prognostics through the viewing of whole slide digital images of human histopathological samples and deep learning AI produced results along with their seamless reporting.

Aiforia Technologies Plc’s (Cambridge, MA, USA) Aiforia viewer provides data-rich decision making to be made by pathologists in an intuitive, quick, and easily readable format. The Viewer software is a completely unique viewer for the clinical pathology workflow with its AI-first approach; enabling the use of Aiforia’s deep learning AI to support the analysis of patient samples. For example, in calculating diagnostic biomarkers of breast cancer before the pathologist has to even take a look; enabling them to then quickly view and accept the result. The pathologist ultimately makes the diagnosis while the AI model enables confidence in this decision making.

The preliminary results that are produced by the Aiforia Viewer software enable case prioritization based on severity and allows the lab to automatically order further staining, ultimately speeding up time to diagnosis. This has the potential to make diagnostic workflows more efficient, enhancing the lab’s overall output efficiency. The CE-IVD marked Aiforia Clinical Suite Viewer is customized to specific disease types, for example breast, prostate, and lung cancer - to enable the most suitable workflows, tools, and results for each patient case. Aiforia is catering widely to pathologists, as they can utilize Aiforia’s CE-IVD marked clinical AI models for breast, lung, and prostate cancer diagnostics along with the Clinical Suite Viewer for significant time savings and workflow improvements in cancer diagnostics.

“At Aiforia we are opening cancer diagnostics to a new era of precision medicine enabled by automated and AI-powered tools during this new epoch of pathology, to help create modern digitized clinical pathology workflows,” said Jukka Tapaninen, CEO of Aiforia Technologies. “With this new CE-IVD marked tool and our 5 CE-IVD marked AI models, and more to come, we can cater to the pathology lab with a comprehensive suite of automated tools for cancer diagnostics.”

“A cancer patient’s medical journey towards healing starts with a correct diagnosis which is most likely made by pathologists,” added Marilyn M. Bui, MD, PhD, Senior Member, Professor of Pathology and Scientific Director of Analytic Microscopy Core at Moffitt Cancer Center & Research Institute. “Pathology and Laboratory Medicine is the critical enabler of precision medicine. Supportive AI tools in cancer diagnostics will augment pathologists’ ability in rendering accurate and timely diagnosis to benefit quality patient care. Our patients deserve the best from the combined power of pathologists and AI.”

Related Links:
Aiforia Technologies Plc 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Monkeypox Virus Real Time PCR Kit
Monkeypox Virus Real Time PCR Kit
Integrated Chemistry & Immunoassay System
Dimension RxL Max
Medical Washer-Disinfector

Print article



view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.